for nonsense mutation Duchenne muscular dystrophy
PTC Therapeutics withdrew its NDA resubmission for Translarna (ataluren) in nonsense mutation Duchenne muscular dystrophy on 2026-02-12. Resubmission had followed prior FDA rejections; the company elected to withdraw rather than pursue further FDA review.
Duchenne muscular dystrophy is a genetic disorder that weakens muscles over time due to missing dystrophin, a protein crucial for muscle structure. Translarna (ataluren) helps cells ignore certain genetic typos (nonsense mutations) so they can produce functional dystrophin protein. By allowing some dystrophin production, the drug may slow muscle degeneration in boys with this specific mutation type.
Duchenne/Becker muscular dystrophy (DBMD) is a genetic disorder that develops in boys. It is caused by a mutation in the gene for dystrophin, a protein that is important for maintaining normal muscle structure and function
Source: ClinicalTrials.gov